Donanemab, which specifically targets pyroglutamate‐modified Aβ, was recently reported to reduce Alzheimer's‐related cognitive decline in a phase 2 clinical trial. PRX012 is a high‐potency IgG1 mAb targeting the N‐terminus of Aβ with 70pM affinity (KD) for Aβ fibrils. In the current ...